"2014-07-14+02:00"^^ . . "Nov\u00E1 technologie antiglaukom\u00E1t\u016F" . " API" . . " new production technology" . . "C\u00EDlem projektu byl v\u00FDvoj nov\u00E9ho validov\u00E9ho postupu pro p\u0159\u00EDpravu Latanoprostu a dal\u0161\u00EDch antigluakomick\u00FDch deriv\u00E1t\u016F za pou\u017Eit\u00ED patentov\u011B nekonfliktn\u00EDch postup\u016F.Sou\u010D\u00E1st\u00ED tohoto c\u00EDle byla validace v\u00FDr. postupu a certifikace pro v\u00FDrobu t\u011Bchto farmaceutik."@cs . "2009-03-01+01:00"^^ . "prostaglanins" . . "Cayman Pharma, LTD is a globally operating company in the area of development, production and marketing of active pharmaceutical ingrediences (API). The production program is focused on narrow specialized section of prostaglandin derivatives. Production of prostaglandin substances has more than 20 years tradition in Cayman Pharma. This historical connection effects the current strategic position of the company in both, positive and negative way. Technologies implemented in the early 80s underwent since then many changes; nevertheless, the efficiency of the production did not increase dramatically. In the context of tighter regulations and more frequent demands from our customers, the company is forced to increase the costs of production, which very negatively effect the competitive advantage of the company. Therefore, there is an urgent need for new research and development of new multipurpose technological process that would allow the production of highly competitive products."@en . . . . " competitive advantage" . "FR-TI1/616" . " glaucoma" . "2012-12-31+01:00"^^ . . . "Cayman Pharma, s.r.o. je glob\u00E1ln\u011B operuj\u00EDc\u00ED firma v segmentu v\u00FDvoje, v\u00FDroby a marketingu aktivn\u00EDch farmaceutick\u00FDch substanc\u00ED (API). Jej\u00ED v\u00FDrobn\u00ED program je zam\u011B\u0159en na \u00FAzkou a specializovanou \u010D\u00E1st, kterou je oblast prostaglandin\u016F. V\u00FDroba prostaglandinov\u00FDch substanc\u00ED m\u00E1 ve spole\u010Dnosti Cayman Pharma, s.r.o. v\u00EDce ne\u017E dvacetiletou tradici. Tato skute\u010Dnost v pozitivn\u00EDm i negativn\u00EDm smyslu ovliv\u0148uje sou\u010Dasnou strategickou pozici spole\u010Dnosti. Technologie, kter\u00E9 byly na po\u010D\u00E1tku 80 let implementov\u00E1ny pro\u0161ly od t\u00E9 doby \u0159adou \u00FAprav, nicm\u00E9n\u011B nedo\u0161lo k pr\u016Flomov\u00E9mu zefektivn\u011Bn\u00ED v\u00FDroby. V souvislosti s postupn\u011B se zp\u0159\u00EDs\u0148uj\u00EDc\u00EDmi se n\u00E1roky nejen regulatorn\u00EDch org\u00E1n\u016F, ale i jednotliv\u00FDch z\u00E1kazn\u00EDk\u016F doch\u00E1z\u00ED k postupn\u00E9mu zvy\u0161ov\u00E1n\u00ED n\u00E1klad\u016F produkce, co\u017E negativn\u011B ovliv\u0148uje konkurenceschopnost spole\u010Dnosti. Proto vyvstala nutnost v\u00FDvoje a v\u00FDzkumu nov\u00E9ho multi\u00FA\u010Delov\u00E9ho technologick\u00E9ho postupu pro p\u0159\u00EDpravu antiglaukomick\u00FDch prostaglandinov\u00FDch deriv\u00E1t\u016F, kter\u00FD by mohl spole\u010Dnosti produkovat vysoce konkurence schopn\u00E9 produkty." . "2012-04-23+02:00"^^ . "1"^^ . . "0"^^ . "1"^^ . . "1"^^ . . . "The aim of this project was the development of the validated process for production of Latanoprost and additianol antiglaukomic derivatives with the use of patent infringement free steps. Part of this aim was validation and certification."@en . . "NEW TECHNOLOGY FOR ANTIGLAUKOMA AGENTS"@en . . " Latanoprost" . . "prostaglanins; glaucoma; Latanoprost; new production technology; competitive advantage; API; GMP"@en . . "0"^^ . "http://www.isvav.cz/projectDetail.do?rowId=FR-TI1/616"^^ . . .